Before 2001, a diagnosis of chronic myelogenous leukemia was almost certainly terminal. But a breakthrough drug pioneered by a doctor at OHSU changed that and made the rare cancer treatable, saving thousands of lives. 

Dr. Brian Druker, chairman of OHSU's Knight Cancer Institute, and Rob Shick, a CML survivor and chair of the Knight Cancer Council, join Laural Porter to celebrate the 20th anniversary of Gleevec's FDA approval, look back on the impact it has had on cancer care, and discuss what's next in the fight to cure cancer.